SCHEDULE: Vanguard Group Reports Zero Beneficial Ownership in Corvus Pharma

The Vanguard Group has filed an amendment to its Schedule 13G, reporting 0% beneficial ownership in Corvus Pharmaceuticals Inc. due to an internal realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 1 to its Schedule 13G for Corvus Pharmaceuticals Inc. Common Stock.
• The filing indicates that The Vanguard Group now holds 0.00 shares, representing 0% of the class of securities.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Corvus Pharmaceuticals Inc. The change reflects an internal administrative realignment by The Vanguard Group rather than a strategic divestment decision, though the removal of a large institutional name from the beneficial ownership list could be perceived with slight caution.

Negatives

• The Vanguard Group, a prominent institutional investor, no longer reports beneficial ownership in Corvus Pharmaceuticals Inc. under its primary reporting entity, reducing its reported stake to 0%.

Risks

• Potential for market misinterpretation that The Vanguard Group, as a whole, has divested its entire stake in Corvus Pharmaceuticals Inc., which could lead to negative investor sentiment or share price impact.
• Reduced transparency regarding the aggregate holdings of all Vanguard entities in Corvus Pharmaceuticals Inc. under a single reporting umbrella.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Corvus Pharmaceuticals Inc. or The Vanguard Group's future investment strategies beyond the internal reporting realignment.

Management Comments

• Ashley Grim, Head of Global Fund Administration for The Vanguard Group, certified that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that internal realignments and changes in reporting structures are common among large, diversified asset managers like The Vanguard Group. While this specific filing indicates a reduction to 0% beneficial ownership for the primary reporting entity, it does not necessarily imply a complete divestment by all Vanguard-affiliated funds. The disaggregated reporting aligns with established SEC guidance for complex organizational structures.

Stakeholder Impact

• Shareholders of Corvus Pharmaceuticals Inc. may observe a change in the reported institutional ownership landscape, potentially leading to questions about the company's institutional support, despite the administrative nature of the change.

Key Dates

Keywords

Corvus Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Holdings, SEC Filing, Common Stock, Investment Management, Disaggregated Reporting